Teva Slams Antitrust Claims In Azilect Patent Row
Teva Pharmaceutical Industries Ltd. said its patent for its Parkinson's disease drug Azilect is valid and would-be generic competitors are overreaching in claims that it broke antitrust laws to secure the...To view the full article, register now.
Already a subscriber? Click here to view full article